Sponsor content
424 result(s) found, displaying 11 to 20
-
Jun-2025Prescription medicine evaluationActive ingredient: gepotidacin mesilate dihydrate.
-
Jun-2025Prescription medicine evaluationActive ingredient: depemokimab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMJJARA momelotinib (as dihydrochloride monohydrate) 200 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMJJARA momelotinib (as dihydrochloride monohydrate) 150 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OMJJARA momelotinib (as dihydrochloride monohydrate) 100 mg film-coated tablet bottle.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: dostarlimab.
-
Australian public assessment report (AusPar)Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
-
Apr-2025Prescription medicine evaluationActive ingredient: Mepolizumab.